ArticleBreast cancer research and treatment2025
Do regularly scheduled visits result in earlier detection of curable breast cancer recurrences?
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reassessing the Role of Regular Physical Examination in Post-treatment Breast Cancer Surveillance.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAn important goal of routinely scheduled physical examination in the post-treatment surveillance of patients with early breast cancer (EBC) is to allow for earlier detection of potentially curable recurrences. We present an updated analysis of recurrence detection, and its potential for curative management, at a single-centre survivorship program that follows ASCO recommendations.
methodsPatients with EBC referred to the Wellness Beyond Cancer Program who had breast cancer recurrence between February 2013 and June 2023 were reviewed. Descriptive analyses were used to present patient and disease characteristics stratified by type of recurrence and mode of cancer detection.
resultsOf 389 first recurrences, 250 were distant (64.3%), 75 local (19.3%), and 64 (16.5%) contralateral new breast primaries. Distant recurrences were primarily detected via patient-reported symptoms (220/250, 88.0%). 42.7% (32/75) of ipsilateral breast recurrences were detected by patients and 53.3% (40/75) by routine imaging. Contralateral breast primaries were primarily detected by routine imaging 71.9% (46/64) and patient-reported symptoms 25.0% (16/64). 2.1% (8/389) recurrences were detected by healthcare providers, 3 were coincidental intraoperative findings and 1.3% (5/389) were detected by healthcare providers at routinely scheduled follow-up visits. Of the 5 recurrences detected at routinely scheduled follow-up visits, only 0.3% (1/389) was potentially curable.
conclusionDespite following ASCO guidelines, potentially curable recurrences are rarely detected by healthcare providers at routinely scheduled follow-up appointments. Our data suggests that approximately 87,670 follow-up visits were required for healthcare providers to detect one curable recurrence. Updated evidence-based guidelines are required to optimise the post-treatment surveillance procedures.
Indexed as
Identifiers
40764879What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.